75 related articles for article (PubMed ID: 35182277)
1. Effectiveness of neutralizing antibody cocktail in hemodialysis patients: a case series of 20 patients treated with or without REGN-COV2.
Arikawa S; Fukuoka K; Nakamoto K; Kunitomo R; Matsuno Y; Shimazaki T; Saraya T; Kawakami T; Kishimoto M; Komagata Y; Kurai D; Ishi H; Kaname S
Clin Exp Nephrol; 2022 May; 26(5):476-485. PubMed ID: 35182277
[TBL] [Abstract][Full Text] [Related]
2. REGN-COV2 antibody cocktail in patients with SARS-CoV-2: Observational study from a single institution in Japan.
Sakurai A; Marshall S; Ogasawara T; Ogasawara T; Aoka Y; Sakura H; Uchigata Y; Ogawa T
J Infect Chemother; 2022 Jul; 28(7):943-947. PubMed ID: 35414436
[TBL] [Abstract][Full Text] [Related]
3. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.
Weinreich DM; Sivapalasingam S; Norton T; Ali S; Gao H; Bhore R; Musser BJ; Soo Y; Rofail D; Im J; Perry C; Pan C; Hosain R; Mahmood A; Davis JD; Turner KC; Hooper AT; Hamilton JD; Baum A; Kyratsous CA; Kim Y; Cook A; Kampman W; Kohli A; Sachdeva Y; Graber X; Kowal B; DiCioccio T; Stahl N; Lipsich L; Braunstein N; Herman G; Yancopoulos GD;
N Engl J Med; 2021 Jan; 384(3):238-251. PubMed ID: 33332778
[TBL] [Abstract][Full Text] [Related]
4. Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy.
Taha Y; Wardle H; Evans AB; Hunter ER; Marr H; Osborne W; Bashton M; Smith D; Burton-Fanning S; Schmid ML; Duncan CJA
Ann Clin Microbiol Antimicrob; 2021 Dec; 20(1):85. PubMed ID: 34969393
[TBL] [Abstract][Full Text] [Related]
5. Safety of casirivimab/imdevimab administration in a SARS-CoV-2 positive maintenance dialysis patient in Japan.
Terakawa K; Katagiri D; Shimada K; Sato L; Takano H
CEN Case Rep; 2022 Aug; 11(3):328-332. PubMed ID: 35000134
[TBL] [Abstract][Full Text] [Related]
6. Duration of infectious viral shedding in patients with mild to moderate COVID-19 treated with REGN-CoV2.
Nomura T; Kitagawa H; Kakimoto M; Kaiki Y; Nazmul T; Miyamori D; Omori K; Shigemoto N; Ito M; Sakaguchi T; Ohge H
J Infect Chemother; 2022 Jul; 28(7):912-917. PubMed ID: 35370078
[TBL] [Abstract][Full Text] [Related]
7. REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters.
Baum A; Ajithdoss D; Copin R; Zhou A; Lanza K; Negron N; Ni M; Wei Y; Mohammadi K; Musser B; Atwal GS; Oyejide A; Goez-Gazi Y; Dutton J; Clemmons E; Staples HM; Bartley C; Klaffke B; Alfson K; Gazi M; Gonzalez O; Dick E; Carrion R; Pessaint L; Porto M; Cook A; Brown R; Ali V; Greenhouse J; Taylor T; Andersen H; Lewis MG; Stahl N; Murphy AJ; Yancopoulos GD; Kyratsous CA
Science; 2020 Nov; 370(6520):1110-1115. PubMed ID: 33037066
[TBL] [Abstract][Full Text] [Related]
8. Real world utilization of REGEN-COV2 at a community hospital.
Ash J; Leavitt R; Dietrich T; Schritter S; Wells J; Santarelli A; Ashurst J
Am J Emerg Med; 2021 Dec; 50():129-131. PubMed ID: 34364110
[TBL] [Abstract][Full Text] [Related]
9. High titer of antibody against the SARS-CoV-2 spike protein among patients receiving neutralizing antibody cocktail therapy with REGN-COV.
Sasaki H; Miyata N; Yoshimura Y; Tachikawa N
Infection; 2022 Jun; 50(3):771-774. PubMed ID: 35181864
[TBL] [Abstract][Full Text] [Related]
10. Clinical Effectiveness of REGN-COV2 in Patients with COVID-19 in Japan: A Retrospective Cohort Study with a Bayesian Inference.
Amano N; Iwata K; Iwata S
Infect Chemother; 2021 Dec; 53(4):767-775. PubMed ID: 34979607
[TBL] [Abstract][Full Text] [Related]
11. Combined REGN-COV2 Antibody Therapy Immediately Prevented a Patient with Refractory Type 1 Autoimmune Pancreatitis from Contracting SARS-CoV-2 during the Sixth Wave in Japan.
Katsuo C; Kubota K; Tanaka K; Kurita Y; Nakajima A
Intern Med; 2023; 62(12):1765-1770. PubMed ID: 37316279
[TBL] [Abstract][Full Text] [Related]
12. Melatonin and REGN-CoV2 combination as a vaccine adjuvant for Omicron variant of SARS-CoV-2.
Haskologlu IC; Erdag E; Sayiner S; Abacioglu N; Sehirli AO
Mol Biol Rep; 2022 May; 49(5):4061-4068. PubMed ID: 35389130
[TBL] [Abstract][Full Text] [Related]
13. Endogenous antibody responses in REGN-COV2-treated SARS-CoV-2-infected individuals.
Kurshan A; Snell LB; Prior L; Tam JCH; Graham C; Thangarajah R; Edgeworth JD; Nebbia G; Doores KJ
Oxf Open Immunol; 2023; 4(1):iqac012. PubMed ID: 36844257
[TBL] [Abstract][Full Text] [Related]
14. Safety of Intradialytic Bamlanivimab/Etesevimab Administration in Two COVID-19 Dialysis Outpatients.
Gasperoni L; Abenavoli C; Donati G; Scrivo A; Zappulo F; Cingolani A; Hu L; La Manna G
Blood Purif; 2022; 51(10):875-878. PubMed ID: 35108709
[TBL] [Abstract][Full Text] [Related]
15. Neutralizing Monoclonal Antibody Treatment Reduces Hospitalization for Mild and Moderate Coronavirus Disease 2019 (COVID-19): A Real-World Experience.
Verderese JP; Stepanova M; Lam B; Racila A; Kolacevski A; Allen D; Hodson E; Aslani-Amoli B; Homeyer M; Stanmyre S; Stevens H; Garofalo S; Henry L; Venkatesan C; Gerber LH; Motew SJ; Jones JS; Younossi ZM
Clin Infect Dis; 2022 Mar; 74(6):1063-1069. PubMed ID: 34166513
[TBL] [Abstract][Full Text] [Related]
16. Compassionate use of REGN-COV2 in the treatment of COVID-19 in a patient with impaired humoral immunity.
Nguyen H; Salkeld J; Agarwal S; Goodman A
Clin Infect Pract; 2021 Nov; 12():100089. PubMed ID: 34426799
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of monoclonal antibody therapy for COVID-19 patients using a risk scoring system.
Mutoh Y; Umemura T; Ota A; Okuda K; Moriya R; Tago M; Soejima K; Noguchi Y; Bando T; Ota S; Sato T; Hirota S; Hagimoto S; Takei R; Sasano H; Yamano Y; Kataoka K; Yokoyama T; Matsuda T; Kimura T; Ichihara T; Kondoh Y
J Infect Chemother; 2022 Feb; 28(2):352-355. PubMed ID: 34863647
[TBL] [Abstract][Full Text] [Related]
18. Emergent Inpatient Administration of Casirivimab and Imdevimab Antibody Cocktail for the Treatment of COVID-19 Pneumonia.
Phan AT; Gukasyan J; Arabian S; Wang S; Neeki MM
Cureus; 2021 May; 13(5):e15280. PubMed ID: 34194882
[TBL] [Abstract][Full Text] [Related]
19. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
[TBL] [Abstract][Full Text] [Related]
20. Presence of specific SARS-COV2 antibodies in hemodialysis patients and their caregivers after the first wave of COVID-19.
Robert T; Lano G; Resseguier N; Bobot M; Bouchouareb D; Burtey S; de Lamballerie X; Dhorne J; Dussol B; Duval A; Faraut J; Fourié T; Giaime P; Hallah M; Jaubert D; Jéhel O; Legris T; Liotatis S; Moal V; Ninove L; Pedinielli N; Pelletier M; Romeu-Giannoli M; Saba M; Sallée M; Samson L; Saveanu A; Scarfoglière V; Sebahoun P; Vial R; Von Kotze C; Brunet P; Lebrun G; Bataille S; Jourde-Chiche N
Sci Rep; 2022 Jul; 12(1):11972. PubMed ID: 35831388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
